Allogeneic Tumor Cell Vaccination in Patients With Solid Tumors

This study has been withdrawn prior to enrollment.
(PI (Prof. Slavin) not longer work at Hadassah)
Sponsor:
Collaborator:
The International Center for Cell Therapy & Cancer Immunotherapy (CTCI)
Information provided by:
Hadassah Medical Organization
ClinicalTrials.gov Identifier:
NCT00148993
First received: September 7, 2005
Last updated: April 7, 2011
Last verified: July 2005

September 7, 2005
April 7, 2011
July 1998
Not Provided
Investigate the feasibility of anti-tumor immune response by allogeneic tumor cell vaccine using tumor cells that share MHC determinants with the patient.
Same as current
Complete list of historical versions of study NCT00148993 on ClinicalTrials.gov Archive Site
Investigate the feasibility of immune responses against cancer cells by combining allogeneic TCV with indomethacin, cimetidine, tetanus and rIL-2.
Same as current
Not Provided
Not Provided
 
Allogeneic Tumor Cell Vaccination in Patients With Solid Tumors
Allogeneic Tumor Cell Vaccination in Patients With Solid Tumors

The goal of this study is to apply allogeneic tumor cell vaccination for immunotherapy in patients with micro-metastatic disease and/or in patients at high risk disease progression. The present study will use allogeneic tumor cell lines for tumor cell vaccines that share MHC determinants with the patient aiming to overcome possible restriction of antigen presentation.

Not Provided
Interventional
Phase 1
Phase 2
Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Metastatic Solid Tumors
Biological: Tumor Cell Vaccine
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Withdrawn
100
July 2005
Not Provided

Inclusion Criteria:

  • Patients with measurable metastatic disease or disease resistant to chemotherapy or with minimal residual disease at high risk to relapse.

Exclusion Criteria:

  • Karnofsky less than 60%. Unrelated condition requiring the use of any cytotoxic agents or immunosuppressive agents which may interfere with optimal immune response.
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Israel
 
NCT00148993
100798-HMO-CTIL
Not Provided
Shimon Slavin MD, The International Center for Cell Therapy & Cancer Immunotherapy (CTCI)
Hadassah Medical Organization
The International Center for Cell Therapy & Cancer Immunotherapy (CTCI)
Principal Investigator: shimon slavin, MD The International Center for Cell Therapy & Cancer Immunotherapy (CTCI)
Hadassah Medical Organization
July 2005

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP